The Ensign Group, Inc.

Services-Skilled Nursing Care Facilities

ENSGSolid11 of 11 basics passed

$171.80

+0.18%

Market cap $10.0B

$171.80

+0.18%

Market cap $10.0B

Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations.

It is a $10.0B healthcare company. Revenue grew 18.9% over the last year, it keeps 7¢ of every dollar of sales as profit, and its net debt equals ~2.7 years of free cash flow. It trades at 26.4× earnings — around the middle of its own history.

Website: ensigngroup.net
Location: San Juan Capistrano, CA
Employees: 46 000
Sector: Healthcare
Founded: 1985

Share price · 3 years

$96.93 → $171.80+77.2%

price only — dividends excluded

Key facts · TTM

Revenue: total sales; $5.49B
Profit: keeps 7¢ of every $1 sold; $379M
Free cash flow: cash left after running the business; $608M
Net debt: debt minus cash on hand; $1.63B
P/E: years of profit in the price; 26.4
EPS: earnings per share, TTM; $6.43
Dividend: pays out 4% of profit · 2% of FCF; 0.15%
Shares: up 13% since 2016 — dilution; 58.9M
Volatility: beta vs the market — under 1 swings less; 0.67

Revenue, last 10 years

52-week range

Low $147.13$171.80High $215.83

Today's price is 36% of the way from the year's low to its high.

P/E vs its history5y

26.4×median 26.2×

Higher than 52% of past days — around the middle of its own history.

Valuation vs own history

P/E

26.4×

48%

P/S

1.8×

49%

EV/EBITDA

25.1×

50%

P/B

4.1×

77%

FCF yield

4.2%

49%

Share of the last ~5 years that was pricier than today (in line with its own history). Based on the daily valuation record.

Insider activity · 90 days

-$153Knet selling

Purchases$0

Sales$153K

Insiders trading, last 14d0 buy · 0 sell

Standing in Healthcare

Size$10.0Btop 87%
Revenue growth+19%top 22%
Net margin7%top 55%
Return on equity17%top 40%
P/E26.4×top 52%
Dividend yield0.15%top 96%

Ranked against 98 Healthcare companies with a full CV — for P/E, lower ranks higher.

Skills

Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.

Strong growth; Moat lags behind.

Valuation69

P/E vs own history52th pct · 12/25
FCF yield6.1% · 20/25
P/S1.8x · 25/25
EV/EBITDA17.0x · 12/25

Growth80

Revenue CAGR17.8% · 20/25
Net income CAGR15.3% · 20/25
EPS CAGR ~5Y13.8% · 20/25
Fwd implied growth25.0% · 20/25

Profitability57

ROIC8.9% · 12/25
ROE16.5% · 20/25
Net margin6.9% · 13/25
Operating margin8.5% · 12/25

Health74

Altman Z3.00 · 25/25
Current ratio1.21 · 12/25
Interest coverage34.7x · 25/25
Net cash / debtD/A 30% · 12/25

Quality65

Piotroski F5/9 · 15/25
Beneish M-2.58 · 25/25
FCF conversionn/a · 0/25
Margin stabilityσ 2.2% · 25/25

Moat49

ROIC >12% years3/10 yrs · 6/25
Median gross margin20.6% · 6/25
FCF-positive years9/9 yrs · 25/25
Worst-year net marginworst 2.2% · 12/25

How the scores work →

Experience

The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.

FY2025Financial
Best year on record
$344M net income
FY2016Financial
Profitable every year on record
10 consecutive profitable years in our data
FY2016Financial
Revenue already above $1B
$1.65B in first reported year
FY2016Financial
Positive free cash flow every year since
10-year streak
1985Founded
The group represented 8,000 veterans nationwide. (After Ensign's death, the Citizen Soldier website went…

Achievements

Verifiable track record, straight from the reported numbers.

$10 000 invested in 2021 would be worth ~$22 632 today — price return only

$5.1B revenue in FY2025

Revenue up 18.9% year over year

Profitable 10 years in a row

Positive free cash flow 10 years in a row

46 000 employees

Strengths & watch-outs

What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.

Strengths

Revenue growing 18.9% year over year
Interest covered 34.7× by operating earnings
Altman Z-Score 3.00 — low bankruptcy-risk zone

Watch-outs

Nothing stands out as a concern in the available data.

Qualifications

The basics a company should meet before you research it further. Each check uses the reported numbers.

11 of 11 checks passed

Revenue growing — the company sells more than a year ago+18.9% YoY
Profitable — makes more than it spends$379M TTM
Profit growing — earnings are higher than last year+13.9% YoY
Generates cash — cash left after running and investing$608M TTM
Debt under control — could handle its obligations~2.7y of cash flow to repay
Established company — not a micro-cap — lower blow-up risk$10.0B market cap
Not printing shares — share count not ballooning — you keep your slice+5.5% shares over ~5y
Proven track record — years of profitability behind it10/10 profitable years
Financially stable — balance sheet not near distressAltman Z 3.0 — safe
Pays a dividend — returns cash to shareholdersyield 0.15%
Valuation not extreme — price not wildly above earningsP/E 26.4

Peer comparisonThe Ensign Group, Inc. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾

Company	Market cap	P/E	Revenue growth	Net margin	Profile
ENSG this company	$10.0B	26.4	+18.9%	6.9%	Solid
LLY Eli Lilly & Co.	$1.0T	41.6	+49.6%	33.5%	Solid
JNJ Johnson & Johnson	$630.9B	29.9	+8.1%	21.5%	Mixed
ABBV Abbvie Inc.	$488.5B	77.4	+10.4%	9.8%	Mixed
MRK Merck & Co., Inc.	$361.0B	113.2	+4.6%	4.8%	Mixed
UNH UNITEDHEALTH GROUP INCORPORATED (Delaware)	$340.7B	24.1	+6.5%	3.1%	Mixed
NVS Novartis AG	$273.2B	20.3	+9.6%	24.7%	Solid

Head-to-head: ENSG vs LLY · ENSG vs JNJ · ENSG vs ABBV

References

What covering analysts publish about the company — information only, not a recommendation.

Strong buy 4Buy 6Hold 2

Appendix · Financial records

The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.

Profit & lossRevenue $5.49B · net income $379M (TTM)Open ▾

Profit & loss

Revenue and profit over the company's career — the income statement, visualised.

How FY2025 revenue flows to profit

RevenueNet income

Revenue (TTM)

$5.49B

YoY 18.9%

Net income (TTM)

$379M

Margin 6.9%

Gross margin

21.3%

Operating margin

8.5%

P/E ratio

26.4

Dividend yield

0.15%

Income statement — full detail

Figures in USD billions · EPS in USD

	2020	2021	2022	2023	2024	2025
Revenue	2.4	2.6	3.0	3.7	4.3	5.1
Gross profit	0.5	0.6	0.7	0.8	0.9	1.0
Operating income (EBIT)	0.2	0.3	0.3	0.3	0.4	0.4
Net income	0.2	0.2	0.2	0.2	0.3	0.3
EPS (diluted)	3.06	3.42	3.95	3.65	5.12	5.84

Cash flowFree cash flow $608M · operating cash flow $608M (TTM)Open ▾

Cash flow statement

Cash generated by the business and what is left after investment — year by year.

Operating cash flowFree cash flow

Free cash flow (TTM)

$608M

Margin 11.1%

Operating cash flow (TTM)

$608M

Cash flow statement — full detail

Figures in USD billions

	2020	2021	2022	2023	2024	2025
Operating cash flow	0.4	0.3	0.3	0.4	0.3	0.6
Capital expenditure	—	-0.2	-0.1	-0.1	-0.2	-0.2
Free cash flow	0.4	0.1	0.2	0.3	0.2	0.4
FCF margin	15.5%	4.1%	6.1%	7.3%	4.4%	7.3%

Balance sheetAssets $5.46B · net debt $1.63B (FY2025)Open ▾

Balance sheet

How the balance sheet is built — what it owns versus how it is financed.

How $5.46B of assets is financed

59%

41%

Liabilities $3.23B — borrowed moneyEquity $2.23B — owners' stake

Cash vs debt

Total debt $2.21B − cash $572M = net debt $1.63B

Cash on hand covers 26% of debt.

Altman Z-Score

3.00

Safe zone

Interest coverage

34.7x

EBIT ÷ interest expense

ROE

16.5%

Profit per $1 of equity

Balance sheet — full detail

Figures in USD billions

	2020	2021	2022	2023	2024	2025
Cash & equivalents	0.3	0.3	0.3	0.5	0.5	0.6
Total assets	2.5	2.9	3.5	4.2	4.7	5.5
Total liabilities	1.7	1.8	2.2	2.7	2.8	3.2
Total debt	—	1.3	1.6	1.9	2.0	2.2
Equity	0.8	1.0	1.2	1.5	1.8	2.2
Net debt	—	1.0	1.2	1.3	1.4	1.6

Want the live picture — intraday moves, valuation history and full analysis?

Deeper analysis of ENSG on PreMarketPrice

Figures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $171.80 · market cap $10.0B.